Coxib-inhibition of Duodenal Polyp Growth in FAP

Summary

Preliminary data indicate a protective effect on the development of duodenal polyps by coxib treatment. The hypothesis of the present study is that normal therapy doses of rofecoxib for 1 year would stop or reverse the development of premalignant adenomatous lesions in the duodenal mucosa of FAP patients.

Timeline

Start

2003-09

Primary completion

2004-04

Completion

2004-04

Drugs

Indications